Innoviva Launches Nortiva Bio to Develop Long-Acting Oral Drug Platform
Innoviva Inc. (NASDAQ:INVA) has launched Nortiva Bio, a clinical-stage subsidiary focused on developing long-acting oral therapies using its LYNX drug delivery platform acquired from Lyndra Therapeutics in 2025. Additionally, Innoviva Specialty Therapeutics entered an exclusive licensing agreement with Dr. Reddy's Laboratories for the distribution of XACDURO in select international markets.